Human Molecular Genetics, 2002, Vol. 11, No. 20 2395-2407
© 2002 Oxford University Press
Impaired dopamine storage resulting from 
-synuclein mutations may contribute to the pathogenesis of Parkinson's disease
Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
Received July 8, 2002; Accepted August 5, 2002
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the inability to initiate, execute and control movement. Neuropathologically, there is a striking loss of dopamine-producing neurons in the substantia nigra pars compacta, accompanied by depletion of dopamine in the striatum. Most forms of PD are sporadic, though in some cases familial inheritance is observed. In the late 1990s, two mutations in the 
-synuclein gene were linked to rare, autosomal dominant forms of PD. Previously cloned from cholinergic vesicles of the Torpedo electric ray, -synuclein is highly enriched in presynaptic nerve terminals and appears to be involved in synapse maintenance and plasticity. It is expressed ubiquitously in the brain, raising the important question of why dopaminergic neurons are primarily targeted in persons carrying mutations in -synuclein. In this article, we review the current literature on -synuclein and suggest a possible role for this protein in vesicle recycling via its regulation of phospholipase D2, its fatty acid-binding properties, or both. Exogenous application of dopamine, as well as redistribution of vesicular dopamine to the cytoplasm, can be toxic to dopaminergic neurons. Thus, impaired neurotransmitter storage arising from mutations in -synuclein could lead to cytoplasmic accumulation of dopamine. The breakdown of this labile neurotransmitter in the cytoplasm could, in turn, promote oxidative stress and metabolic dysfunction, both of which have been observed in nigral tissue from PD patients.
* To whom correspondence should be addressed at: Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund University, BMC A10, 221 84 Lund, Sweden. Tel: +46 462220529; Fax: +46 462220531; Email: julie.lotharius{at}mphy.lu.se
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Chen, Y. Ding, B. Cagniard, A. D. Van Laar, A. Mortimer, W. Chi, T. G. Hastings, U. J. Kang, and X. Zhuang Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice J. Neurosci., January 9, 2008; 28(2): 425 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ahmad, S. Attoub, M. N. Singh, F. L. Martin, and O. M. A. El-Agnaf {gamma}-Synuclein and the progression of cancer FASEB J, November 1, 2007; 21(13): 3419 - 3430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Qin, D. Hu, S. Han, S. H. Reaney, D. A. Di Monte, and A. L. Fink Effect of 4-Hydroxy-2-nonenal Modification on {alpha}-Synuclein Aggregation J. Biol. Chem., February 23, 2007; 282(8): 5862 - 5870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Mack, V. Beljanski, A. M. Soulika, D. M. Townsend, C. B. Brown, W. Davis, and K. D. Tew "Skittish" Abca2 Knockout Mice Display Tremor, Hyperactivity, and Abnormal Myelin Ultrastructure in the Central Nervous System Mol. Cell. Biol., January 1, 2007; 27(1): 44 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rhoades, T. F. Ramlall, W. W. Webb, and D. Eliezer Quantification of {alpha}-Synuclein Binding to Lipid Vesicles Using Fluorescence Correlation Spectroscopy Biophys. J., June 15, 2006; 90(12): 4692 - 4700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Smith, H. Jiang, Z. Pei, Y. Tanaka, H. Morita, A. Sawa, V. L. Dawson, T. M. Dawson, and C. A. Ross Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity Hum. Mol. Genet., December 15, 2005; 14(24): 3801 - 3811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Truong, D. G. Wilkins, J. Baudys, D. J. Crouch, K. L. Johnson-Davis, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein Age-Dependent Methamphetamine-Induced Alterations in Vesicular Monoamine Transporter-2 Function: Implications for Neurotoxicity J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1087 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. W. Doss-Pepe, L. Chen, and K. Madura {alpha}-Synuclein and Parkin Contribute to the Assembly of Ubiquitin Lysine 63-linked Multiubiquitin Chains J. Biol. Chem., April 29, 2005; 280(17): 16619 - 16624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yavich, H. Tanila, S. Vepsalainen, and P. Jakala Role of {alpha}-Synuclein in Presynaptic Dopamine Recruitment J. Neurosci., December 8, 2004; 24(49): 11165 - 11170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Fleming, J. Salcedo, P.-O. Fernagut, E. Rockenstein, E. Masliah, M. S. Levine, and M.-F. Chesselet Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human {alpha}-Synuclein J. Neurosci., October 20, 2004; 24(42): 9434 - 9440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Eisenhofer, I. J. Kopin, and D. S. Goldstein Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine Pharmacol. Rev., September 1, 2004; 56(3): 331 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Jao, A. Der-Sarkissian, J. Chen, and R. Langen From The Cover: Structure of membrane-bound {alpha}-synuclein studied by site-directed spin labeling PNAS, June 1, 2004; 101(22): 8331 - 8336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. SIDHU, C. WERSINGER, and P. VERNIER Does {alpha}-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J, April 1, 2004; 18(6): 637 - 647. [Abstract] [Full Text] [PDF]
|
|